Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1707-1709. doi: 10.1007/s10096-017-3010-z. Epub 2017 May 21.

Authors

D R Giacobbe¹, A E Maraolo², C Viscoli³

Affiliations

¹ Infectious Diseases Unit, DISSAL, IRCCS AOU San Martino-IST and University of Genoa, L.go R. Benzi, 10, 16132, Genoa, Italy. [email protected].
² Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, 80131, Naples, Italy.
³ Infectious Diseases Unit, DISSAL, IRCCS AOU San Martino-IST and University of Genoa, L.go R. Benzi, 10, 16132, Genoa, Italy.

PMID: 28528405
DOI: 10.1007/s10096-017-3010-z

No abstract available

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Carbapenem-Resistant Enterobacteriaceae / drug effects*
Drug Therapy, Combination*
Enterobacteriaceae Infections / drug therapy*
Enterobacteriaceae Infections / microbiology
Humans
Observational Studies as Topic
Randomized Controlled Trials as Topic
beta-Lactam Resistance / drug effects

Substances

Anti-Bacterial Agents